- The agreement between mAbxience and Egis covers the commercialisation of biosimilars in eight Central and Eastern European countries.
- mAbxience will hold the marketing authorisation, while Egis will handle commercialisation.
mAbxience, partly owned by Fresenius Kabi and Insud Pharma, has entered a strategic agreement with Egis Pharmaceutical PLC to commercialise two biosimilar candidates in Central and Eastern Europe. The partnership encompasses eight countries: Hungary, Poland, Czech Republic, Slovakia, Romania, Bulgaria, Latvia, and Lithuania, with potential expansion to further territories.
Under this agreement, mAbxience will act as the marketing authorisation holder for the biosimilars in the designated regions, while Egis will manage the commercial and marketing operations. The collaboration aims to enhance access to affordable, high-quality therapies in regions where accessibility is crucial.
“This agreement strengthens our presence in the region and reaffirms our dedication to ensuring that life-saving treatments are accessible and affordable,” said José Ramón Millán, Global Partnering & Portfolio Director at mAbxience. “We look forward to working closely with Egis to make a significant impact on patient care.”
Dr. Klara Marton, Business Development Director at Egis, expressed that the partnership aligns with Egis’s mission of improving patient access and outcomes, stating, “We are proud to join forces with a trusted partner like mAbxience.”
Overview of outsourcing trends 
